Aclaris Therapeutics vs Rani Therapeutics
ACRS and RANI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACRS and RANI compare
Aclaris Therapeutics is the larger company, worth 7.0 times as much as Rani Therapeutics ($531M against $75.3M).
Rani Therapeutics grew revenue faster over the last twelve months (306% versus −51.0% for Aclaris Therapeutics).
Rani Therapeutics keeps more of each dollar of sales as profit, with a net margin of −618% compared with −921% at Aclaris Therapeutics.
Aclaris Therapeutics scores higher on the StockData Score (5 against 3 for Rani Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACRS | RANI |
|---|---|---|
| Size and price | ||
| Market cap | $531M | $75.3M |
| Share price | $3.60 | $0.540 |
| Change, 1 year | 55.4% | −72.0% |
| Change, 5 years | −71.4% | −98.2% |
| Beta (5Y) | 0.96 | 1.60 |
| Employees | 73 | 69 |
| StockData Score | ||
| Total score | 5 (better) | 3 |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 64.6× | 15.4× (better) |
| P/B | 4.3× | 1.9× (better) |
| FCF yield | −11.7% (better) | −27.0% |
| Fair value | $1.42 | $0.388 |
| Margin of safety | −155% | −39.1% (better) |
| Growth | ||
| Revenue growth (TTM) | −51.0% | 306% (better) |
| Revenue growth, 5Y average | 3.8% | 28.7% (better) |
| Profitability | ||
| Gross margin | 79.5% | – |
| Operating margin | −1050% | −676% (better) |
| Net margin | −921% | −618% (better) |
| FCF margin | −757% | −417% (better) |
| Return on equity | −59.1% (better) | −179% |
| Return on invested capital | – | −145% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −28.2× |
| Current ratio | 3.46 | 5.31 (better) |
| Altman Z-score | −3.16 | −0.67 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.3% | 32.7% |
| Held by insiders | 13.3% | 30.6% |
| Insider net buying, 12 months | −$1.4M | $49.7K (better) |
| Short interest, % of float | 9.1% | 8.5% |
Go deeper
- ACRS stock overview
- ACRS income statement
- ACRS valuation and score
- RANI stock overview
- RANI income statement
- RANI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.